lactoferrin + immunogenic cell death inducer + BRAF inhibitor

This experimental nanomedicine is a multi-component platform designed for the treatment of BRAF-mutant melanoma. It integrates targeted therapy, immunogenic cell death (ICD) induction, and immune checkpoint inhibition into a single delivery system. The platform consists of pH-responsive liposomes that encapsulate the BRAF inhibitor dabrafenib and the MEK inhibitor selumetinib, both of which are modified with cholesterol to enhance stability. The aqueous core of these liposomes contains ultrasmall lactoferrin (LF) nanoconjugates linked to an ICD inducer, such as doxorubicin, via pH-sensitive hydrazone bonds. The surface of the liposome is decorated with anti-PD-L1 antibodies to target the tumor and block the PD-1/PD-L1 axis. This combined approach aims to inhibit the MAPK pathway to increase tumor antigen expression, induce ICD to activate dendritic cells and overcome immunosuppression, and neutralize PD-L1 to boost the overall antitumor immune response.

Other names

lactoferrin-ICD inducer nanoconjugates integrated with BRAF-inhibitory liposomes